Date & time: September 22 at 12:00-13:00 CEST (UTC + 2)

This webinar is intended for HCPs only

This one-hour webinar brings together two experts to address the evolving landscape of treatment for patients with metastatic colorectal cancer (mCRC) who have progressed beyond first-line therapy.

The session combines a comprehensive review of treatment sequencing algorithms with a focused discussion on real-world evidence supporting the use of granulocyte colony stimulating factor (G-CSF) to manage induced neutropenia and maintain dose intensity.

Preliminary agenda:

• Pr. Pia Osterlund: Treatment algorithms after second line in mCRC, an overview of biomarker-driven sequencing, the role of second- and third-line therapies, and practical guidance on patient selection for trifluridine/tipiracil ± bevacizumab, regorafenib, and fruquintinib.
• Dr. Ian Purcell: G-CSF prophylaxis in trifluridine/tipiracil-treated patients, real-world UK retrospective data on timing, duration, and outcomes of G-CSF use to prevent chemotherapy-induced neutropenia.
• Interactive Q&A, open discussion with speakers on practical challenges in managing patients in the later line mCRC setting.

This webinar is brought to you by Servier, with assistance from Mediahuset